Shares mag. recommending this stock this week. Is this going to be our killer this christmas!!!! any comments anyone?????

From what i can see the movement has been because of large buys. Could be some positive news on the way!

It's coming up to 2006. Cenes' big year. The Traders have their year 2005 profits in their pockets - taking money off those not able to stay in for the long run and now they are thinking of 2006.
Those who stayed the run, and were able to, are about to reap the rewards.
Patience is a virtue demanded of others but seldom employed by the self.

It was related to the completion of a large sell order and positive comment yesterday.


Large CeNes Shr Order May Signal Bottom

Wednesday, December 14, 2005 8:38:46 AM ET
Dow Jones Newswires

1224 GMT [Dow Jones] CeNes Pharmaceuticals (CEN.LN) shares could be close to their lows once the execution of a large sell order is completed, says trader. "Piper Jaffray are clearing up a line of 22M CeNes Pharma that has been about for a while," trader says. "This stock has been dripping into the market for a while and I think this could well mark the lows once any flippers are out of the way." Piper Jaffray not immediately available to comment. CeNes shares have fallen from EUR8.50 since late September. Now they're +1.9% at P6.9p. (PBA/DWE)

Dont know anything about this share, but loads of buying including 500,000 shares bought by the boss.

Still happening, big style but the price doesnt move. Why is that?????

stock hangover! brokers obviously have plenty to get rid of and people who bought cheaper cycling out - give it time for the washout and then watch it motor to 12 within 3 months - prob rest there

stock hangover! brokers obviously have plenty to get rid of and people who bought cheaper cycling out - give it time for the washout and then watch it motor to 12 within 3 months - prob rest there

The Guardian said yesterday

Talk that CeNes Pharmaceuticals (LSE: CEN.L - news) could be given the green light by US regulators to start Phase III clinical trials of its treatment for severe post-operative pain.

Shares recommended Aug 2004 and still the same? Oh dear. Phase 3 my arse. And even then it won't necessarily deliver. Just another aim loser.

although i agree with your analysis, will probably trade 4p-12p over the next 6 months. as ever buy on the cannons sell on the bugles. a merry christmas and a profitable new year to all cen players

All research points to cenes rising in '06. I had the same opinion of seo (+200 per cent in '05) this time last year! IMHO & DYOR of course.

Best wishes to all for the new year.

jtf


Info:- http://www.fillyaboots.com/f7/forum_posts.asp?TID=1880&KW=cenes

NEWS:Talk that an institution is about to announce it has taken a 3% stake, lifts CeNes Pharmaceuticals. Hopefully pushes share price upwards

A nice little snippet of news:

CeNeS Pharmaceuticals said it has been granted a patent on its short-acting sedatives by the European Patent Office (EPO).

The patent covers a series of sedative compounds, including CNS 7056X, which are in pre-clinical development.

The EPO is the first to grant the patent.

The company said national applications are pending in other key territories including the US and Japan.

CeNeS' short-acting sedatives are being developed for use in patients undergoing short diagnostic and surgical procedures.

Check this out Cenes Looks like it is going places this year. Buy now, looks very undervalued

Dr.Neil Clark wallstreet interview 17/3/06
http://www.wallstreetreporter.com/linked.php?id=16769

Cenes Moving gradually up, lot of results out soon. Better get in this share quick befor you miss out. Big institutions in.

Let's hope so - it's been a long time coming!

Cenes 26th May 2006 Research Report available at the site below :

http://www.objectivecapital.co.uk/

http://www.proactiveinvestors.com/

Just found this article.Very promising indeed.
The site is free to register on and to read the article.Useful site for those that have not seen it.

CeNes: Future looks bright.
By William Foss.

Restructuring a publicly listed company is a painstaking and tedious operation. Over the past three years, CeNes, a pharmaceutical junior, has been the subject of an intense restructuring program to get the company refocused on drug discovery. Cenes went under the knife in an attempt to streamline it's pipeline and build up a cash reserve.

Thanks h.hairettin.

Good news from CeNeS, particularly the bit about potential revenue stream. I notice someone jumped in yesterday with a late reported trade this morning. Must be nice to have inside information.

pth

CeNeS Pharmaceuticals PLC
13 June 2006


Data on CeNeS short-acting sedative to be presented at at the American Society
for Anesthesiology meeting, 2006.


Cambridge, UK, 13th June 2006 - CeNeS Pharmaceuticals plc (AIM: CEN) ('CeNeS' or
'the Company') today announced that four abstracts highlighting the profile of
the short-acting sedative, CNS 7056X, have been accepted for presentation at the
American Society for Anesthesiology (ASA) meeting to be held in Chicago on
14-18th October 2006. One of the abstracts has been selected as a high profile
platform presentation.

The data to be presented at the ASA meeting will highlight the very encouraging
pre-clinical profile of CNS 7056X, including new results showing a rapid onset
and offset of sedative action and rapid metabolism by human liver samples. The
compound is being developed primarily as a sedative for short non-surgical and
surgical procedures. In addition, on the basis of these new data, CeNeS is now
evaluating the potential of CNS 7056X for use in the induction and maintenance
of anaesthesia. Pre-clinical studies to evaluate the potential of CNS 7056X in
these additional indications are being undertaken at The University of
Strasbourg, The University of Adelaide and under a Material Transfer Agreement
at a major pharmaceutical company. The evaluation will complete in the second
half of 2006. Extending the development of CNS 7056X to include the induction
and maintenance of anaesthesia could double the estimated potential market
opportunity to over 400m.

CNS 7056X is the lead compound of a series that was assigned to CeNeS from
GlaxoSmithKline in November 2003. Pre-clinical development work is ongoing with
the intention of filing an IND in the U.S. in 2006. Thereafter, CeNeS is
planning to conduct the first proof of concept Phase I study in the U.S., a
major potential market for short acting sedatives.


Neil Clark, Chief Executive, commented: 'The American Society for Anesthesiology
meeting is the largest gathering of anaesthesiologists in the world with up to
18,000 attendees expected. We are delighted to see that data on our short-acting
sedative will be presented at such an important conference. We are also very
excited by the potential of CNS 7056X for the additional indications of
induction and maintenance of anaesthesia. Presenting at this conference will
enable to us to access key opinion leaders and potential global partners of CNS
7056X'